share_log

Reported Earlier, ARCA Biopharma Updates Special Dividend To $1.613/Share In Preparation For Oruka Therapeutics Merger

Reported Earlier, ARCA Biopharma Updates Special Dividend To $1.613/Share In Preparation For Oruka Therapeutics Merger

方舟生物醫藥更新特別股息至每股1.613美元,爲奧魯卡治療合併做準備
Benzinga ·  08/27 03:30

ARCA biopharma updates the previously announced final amount of the special cash dividend (the "Special Dividend"), which will now equal $1.613 per share of ARCA's common stock, payable on August 28, 2024, to ARCA's stockholders of record as of August 26, 2024. The Special Dividend was declared by ARCA's Board of Directors on August 16, 2024, in connection with the previously announced merger (the "Merger") with Oruka Therapeutics, Inc. ("Oruka"), pursuant to the Agreement and Plan of Merger and Reorganization, dated April 3, 2024 (the "Merger Agreement"). The exact amount of the Special Dividend was calculated in accordance with the Merger Agreement and based on ARCA's reasonable, good faith approximation of the amount by which ARCA's net cash, as determined prior to the closing of the Merger, will exceed $5,000,000.

方舟生物醫藥更新了此前宣佈的特別現金股息的最終金額,現在將達到每股1.613美元的方舟普通股,於2024年8月28日支付給2024年8月26日和方舟股東。特別股息是由方舟董事會於2024年8月16日宣佈的,以與之前宣佈的與Oruka Therapeutics, Inc.(「 Oruka」)的合併(「 合併」)相關,根據2024年4月3日簽署的合併和重組協議(「 合併協議」)計算專項股息的確切金額與方舟在合併完成前根據合併協議確定的方舟淨現金相比,超過500萬美元的數量的合理、善意估計有關。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論